Hyderabad, Sep 25: On Thursday, Sep 25 Suven Life Sciences Limited, a Drug discovery and development company, announced that it had received permission from the Drug Controller General of India (DCGI) to conduct Phase I clinical trials of SUVN-502.
SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a non-peripheral, CNS receptor site 5-HT6, is intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia, a press release said here.
Suven was also holding discussions with potential licensing partners for this compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets. The company was targeting to launch the molecule in 2012, the release added.